Molecular Partners, Allergan expand alliance to develop DARPin products
The first agreement calls for the design, development and commercialization of a potent dual anti-VEGF-A/PDGF-B DARPin (MP0260) and its corresponding backups to treat age-related macular degeneration (AMD) and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.